The state and consequences of dermatology drug prices in the United States
UMass Chan AffiliationsDivision of Dermatology, Department of Medicine
pharmacy benefit managers
Pharmacoeconomics and Pharmaceutical Economics
MetadataShow full item record
AbstractIn 2014, Medicare expenditures increased 12%, the largest increase reported since 2002, resulting in major concerns by both patients and physicians. Although costs are rising for both specialty drugs and generic medications,out-of-pocket costs, restrictive formularies,and health plan bureaucracies are limiting patients' access to necessary medications. In response, the Regulatory Policy Committee of the American Academy of Dermatology (AAD)/Association (AAD/A) convened a Task Force on Drug Pricing and Transparency. This editorial summarizes the issues addressed by the task force along with relevant AAD/A policy.
SourceJ Am Acad Dermatol. 2016 Sep;75(3):603-5. doi: 10.1016/j.jaad.2016.03.053. Epub 2016 Jul 13. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/29074
Full author list omitted for brevity. For full list of authors see article.
Related ResourcesLink to Article in PubMed